Dysphonia and Vagus nerve dysfunction
SLN block with Dr. McGarey for globus sensation and vagus neuropathy in Oct. 2025 which was effective. Planned second SLN block, but patient felt it wasn't needed. However, when she last saw Dr. McGarey she was complaining of return of dysphonia symptoms and was again referred for therapy. 

Long-term stimulant laxative use is rarely associated with serious complications in clinical practice because the feared "cathartic colon" and enteric nervous system damage have not been demonstrated in well-controlled human studies at therapeutic doses. Historical case reports describing colonic neuropathy and melanosis coli were confounded by supratherapeutic dosing, laxative abuse, or underlying motility disorders themselves—not the agents used appropriately 1. Modern evidence supports that bisacodyl and senna (Senna-Lax) do not cause structural impairment of enteric nerves or smooth muscle when used as directed, and concerns about carcinogenicity have been refuted by genotoxicity and long-term rodent studies 1.

Why serious long-term complications are rarely encountered

• Reversible mucosal changes only: At recommended doses, any histological alterations (e.g., surface epithelial cell changes, melanosis coli) are reversible and functionally insignificant; no prospective controlled trials have shown permanent ENS or smooth muscle damage from bisacodyl, senna, or sodium picosulfate 1 2.

• "Cathartic colon" is a historical artifact: The classic descriptions of cathartic colon with loss of haustral folds and myenteric plexus degeneration derived from case series of laxative abuse (often 10–18× recommended doses for years) or concomitant neurological disease—not typical clinical use 1. No cases have been reported in patients starting laxatives after 1960 in one review of 240 abuse cases 1.

• Carcinogenicity concerns disproven: Phenolphthalein was withdrawn due to animal carcinogenicity, but bisacodyl and senna lack genotoxic or carcinogenic potential in preclinical and epidemiological data; some studies suggest constipation itself increases colorectal cancer risk, while laxative use may be protective by reducing luminal carcinogen contact time 1.

• Tolerance is uncommon: Contrary to popular belief, tachyphylaxis to stimulant laxatives is rare; pediatric data show weight-adjusted senna doses remain stable over years without progressive dose escalation, and 55% of children on long-term bisacodyl were successfully weaned off after median 18 months without sequelae 3 4.

Clinical implications

ConcernEvidence-based realityEnteric nerve damageNot demonstrated at therapeutic doses; historical reports confounded by abuse or primary motility disorders 1Colorectal cancer riskNo association in epidemiological studies; constipation itself carries higher risk 1Electrolyte disturbancesOnly with misuse/abuse or colon-cleansing regimens; routine use is safe 1Need for "laxative holidays"No evidence supports cycling; continuous use is acceptable if effective 5

The 2024 ASCRS guideline and 2023 AGA/ACG guideline both endorse stimulant laxatives as safe rescue or adjunctive therapy, with the AGA noting that while long-term RCT data are limited, "longer term use is probably appropriate" based on extensive post-marketing experience 6 7. The disconnect between historical fears and modern clinical observation reflects improved understanding of confounding in early case series and the safety of dose-appropriate use.

Sources:

1. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therapeutic Advances in Gastroenterology, 2024
2. Is chronic use of stimulant laxatives harmful to the colon?. Journal of Clinical Gastroenterology, 2003
3. Longitudinal changes in senna-based laxative dosing in pediatric constipation: a single-center retrospective study. Journal of Pediatric Surgery, 2026
4. Long-term use of bisacodyl in pediatric functional constipation refractory to conventional therapy. Journal of Pediatric Gastroenterology and Nutrition, 2020
5. Myths and misconceptions about chronic constipation. The American Journal of Gastroenterology, 2005
6. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the evaluation and management of chronic constipation. Diseases of the Colon and Rectum, 2024
7. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology, 2023

   E-1 mcg/g feces    Interpretation
 
     <100          Severe exocrine pancreatic
                   insufficiency
 
   100-200         Mild to moderate exocrine
                   pancreatic insufficiency
 
     >200          Normal